<DOC>
	<DOCNO>NCT03100955</DOCNO>
	<brief_summary>To establish progression free survival patient extensive stage small cell lung cancer treat cisplatin etoposide plus apatinib</brief_summary>
	<brief_title>A Study Standard Treatment +/- Apatinib Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>Assess progression free survival , overall survival toxicity standard EP regimen combine VEGF tyrosine kinase inhibitor-apatinib . Response measure RECIST response criterion . Toxicity via physical exam , adverse event review , assess sign symptom , quality life assessment blood testing .</detailed_description>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Topoisomerase Inhibitors</mesh_term>
	<criteria>1 . Histologically cytologically verify SCLC , extensive stage 2. WHO performance status 0 , 1 , 2 3 . Age 18 year old 4 . Treatment naive 5 . Anticipated survival 3 month 6 . HB &gt; 90g/L , ANC &gt; 1.5 x 109/L , Platelets &gt; 80 x109 /L 7 . No prognancy 8 . Signed informed consent 1 . Limited stage disease 2 . Metastastic meningitis , spinal compression , Tumor main vesicular less 5mm 3 . Uncontrolled hypertension 4 . Uncontrolled heart failure 5 . Coagulation problem 6 . Surgery , trauma , uncontrolled ulcer 4 week . 7 . Required physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>